Clinical trial for Colorectal Cancer
Official title A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
ClinicalTrials.gov ID: NCT06428409
What this study is testing
What is Sacituzumab tirumotecan?
An investigational biological medicine being studied for colorectal cancer.
Also referred to as MK-2870, SKB264.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to determine how safe the drug is and whether patients’ tumors shrink or disappear when treated alone or with other therapies.
- Who it's for
- Adults with advanced or unresectable colorectal, pancreatic ductal adenocarcinoma, or biliary tract cancer.
- What's involved
- Participants receive sacituzumab tirumotecan, either by itself or together with other cancer treatments, and attend scheduled clinic visits for monitoring and tests.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Unresectable or metastatic colorectal cancer and has received prior therapy for the cancer
- Advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and has received prior therapy for the cancer
- Advanced and/or unresectable biliary tract cancer (BTC) and has received prior therapy for the cancer
- Advanced and/or unresectable BTC and has not received prior therapy for the cancer
- For participants who have received prior therapy for cancer: Has recovered from any side effects due to previous cancer treatment
You likely can't join if
- History of severe eye disease
- For participants who have received prior therapy for cancer: Received prior systemic anticancer therapy including investigational agents within 4...
- History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, has current pneumonitis/ILD, or has suspected ILD or...
The study team makes the final eligibility decision.
Where it is enrolling
- Los Angeles, California, United States
- Aurora, Colorado, United States
- Gainesville, Florida, United States
- Mineola, New York, United States
- New York, New York, United States
- Houston, Texas, United States
- Roanoke, Virginia, United States
- Madison, Wisconsin, United States
- Ottawa, Ontario, Canada
- Montreal, Quebec, Canada
- Temuco, Araucania, Chile
- Santiago, Region M. de Santiago, Chile
- Fuzhou, Fujian, China
- Chengdu, Sichuan, China
- Milan, Lombardy, Italy
- Roma, Italy
- Kashiwa, Chiba, Japan
- Yokohama, Kanagawa, Japan
- Seoul, South Korea
- Madrid, Madrid, Comunidad de, Spain
+ 4 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Los Angeles, California, United States; Aurora, Colorado, United States; Gainesville, Florida, United States; Mineola, New York, United States; New York, New York, United States; Houston, Texas, United States and 18 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.